Our recent study on PCI timing strategies in patients undergoing TAVI was among the most impactful articles in EuroIntervention 2023!
Great collaborative work! This is a tribute to all co-workers involved in this project ! @barbanti_marco @costagiuliano90 @MichaelJoner3 – at Munich, Germany
Tobias Rheude retweeted
Here is the customary year-end review of the most impactful articles of 2023 on EuroIntervention. The calculation is based on the number of citations in the calendar year by articles published in 2023 (normalized for the number of months online), so it has nothing to do with the impact factor (for now...) but more with a kind of 'Immediacy Index’, which tells us what our community is currently discussing. Certainly about TAVI, but also pay attention to the rise of cardiogenic shock, pulmonary embolism, INOCA, LAAO, and renal denervation.
In this ranking, I note the almost disappearance of articles on 'pure coronary' (although one could argue that the first position is jointly held), as if everything and its opposite has now been said and cited in this field. And it reassures me to see that 7 out of 10 articles are original research (not to mention two EAPCI documents and one State of the Art, two defining categories): a sign that the path we have taken with the Journal is bearing fruit, with a positive outlook in 2024, where you will see several innovations.
Thanks to everyone (readers, authors, reviewers, authors) for another year of EuroIntervention.
Tobias Rheude retweeted
The SAPIEN 3 and EVOLUT LR trials offer a good platform for assessing the long-term durability of TAVI. However, potential differences between these trials warrant careful consideration in comparative analyses. Head-to-head trials powered for clinical endpoints remain critical.
Tobias Rheude retweeted
Major Study including >1 million patients from 24 US centers demonstrating the mortality burden of the different degrees of severity of aortic stenosis. And with an editorial from the godfather of AS Dr. E. Braunwald!
pubmed.ncbi.nlm.nih.gov/3787…
Tobias Rheude retweeted
Die #DGK JT 2024 mag gefühlt noch in weiter Ferne liegen, aber die Deadline für Abstract-Eingabe ist - wie jedes Jahr zu meiner Überraschung - schon am 13.11.2023 um 12:00 Uhr!
Nutzt die Gelegenheit, eure Forschung zu präsentieren: jt2024.dgk.org/abstract-eing… @DGK_org @YoungDgk
Tobias Rheude retweeted
This study showed that in patients with severe AS and stable CAD scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. #EAPCI ow.ly/h7Nu50PPbNy
Tobias Rheude retweeted
NEW ISSUE OUT🔥 A State-of-the-Art on cerebral embolic protection during transcatheter heart interventions; a debate on guided DAPT; the 3-year outcomes of the EuroCTO trial; and more. #EAPCI ow.ly/Soxh50PMBrO
Tobias Rheude retweeted
3-Year Outcomes From the Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE) | JACC: Cardiovascular Interventions jacc.org/doi/10.1016/j.jcin.…
Tobias Rheude retweeted
Comparison of different percutaneous revascularisation timing strategies in patients undergoing #TAVI
Read this new #EAPCI/PCR Journal Club review ✍️🏼 of an article selected in @EuroInterventio by @ABeneduceMD & Omar Alessandro Oliva:
pcronline.com/PCR-Publicatio…
#TAVR
Tobias Rheude retweeted
In the international REVASC-TAVI registry, among patients with severe aortic stenosis and stable CAD scheduled for TAVI, PCI "after" the aortic intervention was associated with better 2-year outcomes compared with other revascularisation timing strategies. eurointervention.pcronline.c…
Tobias Rheude retweeted
#REVASC_TAVI Registry | In patients with #SevereAS & #stableCAD, PCI staged after TAVI seems to be associated with better 2 yr clinical outcomes when compared with other revascularization timing strategies.
@EuroInterventio @PCRonline #Cardiotwitter
🔗➡️eurointervention.pcronline.c…
Tobias Rheude retweeted
New evidence on coronary revascularization in TAVI setting from the REVASC-TAVI Registry: should we pospone PCI after TAVI? @EuroInterventio eurointervention.pcronline.c…
Different PCI timing strategies in TAVI patients are discussed daily in our clinical practice. ➡️ Check out our latest collaborative work from the REVASC-TAVI registry now available in @EuroInterventio Great team work of 30 international TAVI centers! – at Munich, Germany
Tobias Rheude retweeted
Congrats @TRheude on this important Article!!!👏🫀
Must Read The REVASC-TAVI registry on. --> Role of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies.
@EuroInterventio
eurointervention.pcronline.c…
Tobias Rheude retweeted
Es ist Zeit etwas dagegen zu tun. Nationale Herz-Allianz @DGK_org @YoungDgk @AGIKinterv @PCSchulzeMD @JBauersachsMD @TRassafMD @AGEP_DGK @Echo_DGK_GER @DGK_AG3 @AG21_DGK
Neue Studie: Bei der durchschnittlichen #Lebenserwartung erreicht Deutschland im westeuropäischen Vergleich nur Schlusslichtpositionen. Unter 16 Ländern belegt DE bei den Männern mit 78,7 Jahren Rang 15, bei den Frauen mit 83,5 Jahren Rang 14. Mit Grund dafür… 🧵 /3
Tobias Rheude retweeted
⭐️Tomorrow at 7️⃣pm CET the #CardioJournalClub is live
➡️Join Prof. @sbrugaletta & the presenter @Riccardo_Rin who will discuss on the latest @NEJM publication on Intravascular Imaging Guided PCI - RENOVATE-COMPLEX-PCI RCT
🗓Thu 27th Apr
⏰7.00 pm (Rome)
➡️DM for ZOOM link🔗
Tobias Rheude retweeted
First in human experience with Sapien X4 lead by Dr Webb. The St Paul’s experience. jacc.org/doi/10.1016/j.jcin.… @David_Meier_ @EdwardsLifesci @TCTMD @JACCJournals
Tobias Rheude retweeted
In patients with HFrEF, moderate AS is associated with increased rates of HF hospitalization and mortality. Moderate AS almost as bas as severe AS. Stay tuned for the results of TAVR-UNLOAD, PROGRESS, and EXPAND TAVR II trials.
From @jaccjournals jacc.org/doi/10.1016/j.jacc.…



































